Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TWi BiotechnologyROCO:6610 +0.56%31 Receivables Turnover is 0.00 as of Jun. 2026. GuruFocus rates ROCO:6610 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 845 Biotechnology companies, TWi Biotechnology ranks worse than 118343.08% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. TWi Biotechnology's Revenue for the
six
months ended in Jun. 2026 was NT$0.00 Mil. TWi Biotechnology's average Accounts Receivable for the
six
months ended in Jun. 2026 was NT$0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
TWi Biotechnology Receivables Turnover Related Terms
TWi Biotechnology Receivables Turnover Historical Data
* Premium members only.
The historical data trend for TWi Biotechnology's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6610 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, TWi Biotechnology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TWi Biotechnology Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TWi Biotechnology's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where TWi Biotechnology's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TWi Biotechnology (ROCO:6610) has a Receivables Turnover of 0.00 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TWi Biotechnology and its competitors. According to the industry distribution chart, TWi Biotechnology ranks #999999 out of 845 companies in the Biotechnology industry.
Is TWi Biotechnology's Receivables Turnover too high?
TWi Biotechnology's current Receivables Turnover is 0.00. Based on the distribution chart, TWi Biotechnology ranks #999999 out of 845 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TWi Biotechnology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does TWi Biotechnology's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TWi Biotechnology ranks #999999 out of 845 companies for Receivables Turnover. This places TWi Biotechnology in the lower half of its industry. The industry median Receivables Turnover is 5.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.22, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TWi Biotechnology and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TWi Biotechnology's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TWi Biotechnology stock overvalued right now?
TWi Biotechnology (ROCO:6610) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. TWi Biotechnology's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For TWi Biotechnology (ROCO:6610), the current Receivables Turnover is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs for unmet medical needs, particularly in the diseases associated with innate immunity. The pipeline products of the company comprise AC-201, AC-203, and AC-701.
31GF Score
Get the complete analysis for ROCO:6610
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6610 has been successfully added to your 
